Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Scribe Therapeutics logo — CRISPR by Design™

Scribe Therapeutics

CRISPR by Design™

Founded 2017 United States Alameda, United States 87 employees Series B Total: $140.00M Biotechnology

General Information

Company Name Scribe Therapeutics
Founded Year 2017
Location United States Alameda, United States
Employees 87
Industries Biotechnology
Funding Stage Series B
Business Model B2B, B2B2C, D2C
Revenue Model Licensing, Performance Based, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Scribe Therapeutics. To contact Scribe Therapeutics, visit scribetx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Scribe Therapeutics compare?

A PDF of Scribe Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Scribe Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Scribe Therapeutics

Scribe Therapeutics, founded in 2017, is a cutting-edge player in the Biotechnology sector. With the motto "CRISPR by Design™," the company focuses on creating genetic medicines through an innovative approach to genetic modification.

The firm is headquartered in the United States and seeks to revolutionize the landscape of genetic treatments. Leveraging the robust potential of CRISPR technology, Scribe Therapeutics is setting the stage for advancements in genetic medicine.

Most recently, the company secured a Convertible Note investment on 01 May 2023, illustrating continued investor interest in their technology and vision. This investment involved Prevail Therapeutics, a company with a solid track record in the biotechnology industry. This backing underscores confidence in Scribe Therapeutics' ability to innovate and execute in this competitive space.

Business keywords: Genetic Medicines, CRISPR Technology, Gene Editing, Genetic Modification, Precision Medicine, Life Sciences, Biopharmaceuticals, Genomic Innovation, Therapeutic Development, Genome Engineering, Molecular Biology, Medical Biotechnology

Services & Products

CRISPR genetic engineering
therapeutic development
preclinical data research
strategic partnerships

Target Customers

individuals with genetic predispositions patients with cardiometabolic diseases pharmaceutical companies medical researchers

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note Undisclosed 1
Prevail Therapeutics
Prevail Therapeutics
01 May 2023
Series B $100.00M 9
RA Capital Management Andreessen Horowitz/ a16z Menlo Ventures
RA Capital Management, Andreessen Horowitz/ a16z +7
01 Mar 2021
Series A $20.00M 1
Biogen
01 Oct 2020
Spinout Undisclosed 1
University of California, Berkeley
01 Dec 2018
Series A $20.00M 1
Andreessen Horowitz/ a16z
Andreessen Horowitz/ a16z
01 Jan 2018

Scribe Therapeutics Alternatives & Competitors

View All Alternatives
Scribe Therapeutics vs
Modalis Therapeutics
Modalis Therapeutics United States

Modalis is an emerging biotech company that develops therapeutics using CRISPR based technology

IPO
23 employees
Biotechnology, Health Care
Scribe Therapeutics vs
Arbor Biotechnologies
Arbor Biotechnologies United States

Genetic medicines for genetic diseases

103 employees
Biopharma, Biotechnology
Scribe Therapeutics vs
Editas Medicine
Editas Medicine United States

What If You Could Repair Broken Genes?

IPO
178 employees
Biotechnology
View all alternatives

FAQ About Scribe Therapeutics

CRISPR by Design™
Scribe Therapeutics was founded in 2017.
Scribe Therapeutics is headquartered in Alameda, United States.
Scribe Therapeutics operates in Biotechnology. Its work centres on Genetic Medicines, CRISPR Technology, Gene Editing and Genetic Modification. Its customers include individuals with genetic predispositions, patients with cardiometabolic diseases and pharmaceutical companies.
Scribe Therapeutics has a B2B, B2B2C and D2C business model. Its revenue comes from Licensing, Performance Based and Project Based.
Scribe Therapeutics has approximately 87 employees.
Scribe Therapeutics has completed 5 funding rounds, raising a total of $140.00M. The latest funding stage is Series B.
Scribe Therapeutics offers: CRISPR genetic engineering, therapeutic development, preclinical data research, strategic partnerships.
Top alternatives and competitors to Scribe Therapeutics include Modalis Therapeutics, Arbor Biotechnologies, Editas Medicine, Beam Therapeutics, Shape Therapeutics Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Scribe Therapeutics and Modalis Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Scribe Therapeutics, https://bouncewatch.com/company/scribe-therapeutics, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes